Would you recommend maintenance therapy with a PARP inhibitor for BRCA+ patients with advanced uterine serous cancer?
Since no data exists or is pending, and the two disease processes are similar, should we consider PARP inhibition in this setting? This is assuming the patient does not have a Her2/neu mutation.
Answer from: at Academic Institution
This is a data free zone, so I would hesitate to make a recommendation to use a PARP in this setting. Although, theoretically this should work if the patient has BRCA gene mutation. This would be an excellent question to answer in the form of a clinical trial similar to what Fader et al did for HER2...
Sign in or Register to read more